Pathogenicity of Type I Interferons in Mycobacterium tuberculosis
International Journal of Molecular Sciences · 15.02.2023 · 24 (4) · 3919
DOI: 10.3390/ijms24043919 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift International Journal of Molecular Sciences, online erschienen am 15.02.2023. Verfasst von Akaash Mundra und 9 weiteren Autor:innen. Beteiligte Einrichtung: College of Osteopathic Medicine of the Pacific, Western University of Health Sciences, Pomona, CA 91766, USA. Hauptthemen laut MEDLINE: Mycobacterium tuberculosis, Interferon Type I, COVID-19, Tuberculosis. Die Arbeit wurde bisher 26-mal zitiert (Crossref) und nennt 155 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NHLBI NIH HHS, NIH.
Abstract (Originalsprache)
Tuberculosis (TB) is a leading cause of mortality due to infectious disease and rates have increased during the emergence of COVID-19, but many of the factors determining disease severity and progression remain unclear. Type I Interferons (IFNs) have diverse effector functions that regulate innate and adaptive immunity during infection with microorganisms. There is well-documented literature on type I IFNs providing host defense against viruses; however, in this review, we explore the growing body of work that indicates high levels of type I IFNs can have detrimental effects to a host fighting TB infection. We report findings that increased type I IFNs can affect alveolar macrophage and myeloid function, promote pathological neutrophil extracellular trap responses, inhibit production of protective prostaglandin 2, and promote cytosolic cyclic GMP synthase inflammation pathways, and discuss many other relevant findings.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- College of Osteopathic Medicine of the Pacific, Western University of Health Sciences, Pomona, CA 91766, USA.
- Graduate College of Biomedical Sciences, Western University of Health Sciences, Pomona, CA 91768, USA.
ORCID-Profile: Akaash Mundra, Aram Yegiazaryan, Victor Bonavida, Mitchell Frame, Vishwanath Venketaraman
Förderung
- NHLBI NIH HHS
- NIH
Zitieren
APA
Mundra, A., Yegiazaryan, A., Karsian, H., Alsaigh, D., Bonavida, V., Frame, M., May, N., Gargaloyan, A., Abnousian, A., & Venketaraman, V. (2023). Pathogenicity of Type I Interferons in Mycobacterium tuberculosis. International Journal of Molecular Sciences, 24(4), 3919. https://doi.org/10.3390/ijms24043919
Vancouver
Mundra A, Yegiazaryan A, Karsian H, Alsaigh D, Bonavida V, Frame M, et al. Pathogenicity of Type I Interferons in Mycobacterium tuberculosis. International Journal of Molecular Sciences. 2023;24(4):3919. doi:10.3390/ijms24043919
BibTeX
@article{Mundra2023,
author = {Mundra, Akaash and Yegiazaryan, Aram and Karsian, Haig and Alsaigh, Dijla and Bonavida, Victor and Frame, Mitchell and May, Nicole and Gargaloyan, Areg and Abnousian, Arbi and Venketaraman, Vishwanath},
title = {Pathogenicity of Type I Interferons in Mycobacterium tuberculosis},
journal = {International Journal of Molecular Sciences},
year = {2023},
volume = {24},
number = {4},
pages = {3919},
doi = {10.3390/ijms24043919}
}
EUVIMED